JP2017507980A5 - - Google Patents

Download PDF

Info

Publication number
JP2017507980A5
JP2017507980A5 JP2016557251A JP2016557251A JP2017507980A5 JP 2017507980 A5 JP2017507980 A5 JP 2017507980A5 JP 2016557251 A JP2016557251 A JP 2016557251A JP 2016557251 A JP2016557251 A JP 2016557251A JP 2017507980 A5 JP2017507980 A5 JP 2017507980A5
Authority
JP
Japan
Prior art keywords
degrees
pharmaceutical composition
disease
compound
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016557251A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017507980A (ja
JP6553081B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/020696 external-priority patent/WO2015142714A1/en
Publication of JP2017507980A publication Critical patent/JP2017507980A/ja
Publication of JP2017507980A5 publication Critical patent/JP2017507980A5/ja
Application granted granted Critical
Publication of JP6553081B2 publication Critical patent/JP6553081B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016557251A 2014-03-17 2015-03-16 アダプター関連キナーゼ1の阻害剤、それを含む組成物、及びその使用方法 Active JP6553081B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461953976P 2014-03-17 2014-03-17
US61/953,976 2014-03-17
PCT/US2015/020696 WO2015142714A1 (en) 2014-03-17 2015-03-16 Inhibitors of adapter associated kinase 1, compositions comprising them, and methods of their use

Publications (3)

Publication Number Publication Date
JP2017507980A JP2017507980A (ja) 2017-03-23
JP2017507980A5 true JP2017507980A5 (US07794700-20100914-C00152.png) 2018-04-12
JP6553081B2 JP6553081B2 (ja) 2019-07-31

Family

ID=52727478

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016557251A Active JP6553081B2 (ja) 2014-03-17 2015-03-16 アダプター関連キナーゼ1の阻害剤、それを含む組成物、及びその使用方法

Country Status (15)

Country Link
US (1) US9682982B2 (US07794700-20100914-C00152.png)
EP (2) EP3719021B1 (US07794700-20100914-C00152.png)
JP (1) JP6553081B2 (US07794700-20100914-C00152.png)
CN (1) CN106103447B (US07794700-20100914-C00152.png)
AR (1) AR099766A1 (US07794700-20100914-C00152.png)
AU (1) AU2015231672B2 (US07794700-20100914-C00152.png)
CA (1) CA2941870C (US07794700-20100914-C00152.png)
DK (2) DK3719021T3 (US07794700-20100914-C00152.png)
ES (2) ES2911388T3 (US07794700-20100914-C00152.png)
HK (1) HK1226065A1 (US07794700-20100914-C00152.png)
HU (1) HUE050975T2 (US07794700-20100914-C00152.png)
PL (2) PL3719021T3 (US07794700-20100914-C00152.png)
PT (2) PT3119783T (US07794700-20100914-C00152.png)
TW (1) TW201620911A (US07794700-20100914-C00152.png)
WO (1) WO2015142714A1 (US07794700-20100914-C00152.png)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104302649B (zh) * 2012-03-09 2017-06-23 莱西肯医药有限公司 基于吡唑并[1,5‑a]嘧啶的化合物、包含它们的组合物及其使用方法
US9737542B2 (en) 2013-10-11 2017-08-22 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
CN109369576B (zh) * 2018-09-19 2020-11-27 上海凌凯医药科技有限公司 一种合成3-甲基氧杂环丁烷-3-(4-硝基苯基)碳酸酯的方法
CA3175970A1 (en) 2020-04-21 2021-10-28 Suma GOPINATHAN Aak1 inhibitors for use in treating viral infections
WO2021216454A1 (en) * 2020-04-21 2021-10-28 Lexicon Pharmaceuticals, Inc. 4-(3-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl)piperazine for use in the the treatment of cov-229e or cov-oc43 coronaviruses infections
WO2023196584A2 (en) * 2022-04-08 2023-10-12 New York University Endocytosis inhibitors and their use for pain treatment

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US6194410B1 (en) * 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
EP1873157A1 (en) * 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
WO2010118207A1 (en) * 2009-04-09 2010-10-14 Schering Corporation Pyrazolo [1, 5-a] pyrimidine derivatives as mtor inhibitors
UA110324C2 (en) * 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
WO2011030139A1 (en) * 2009-09-11 2011-03-17 Astrazeneca Ab 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators
WO2011087999A1 (en) * 2010-01-14 2011-07-21 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidines as mark inhibitors
WO2012034095A1 (en) * 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
CN104302649B (zh) 2012-03-09 2017-06-23 莱西肯医药有限公司 基于吡唑并[1,5‑a]嘧啶的化合物、包含它们的组合物及其使用方法
MX347917B (es) * 2012-03-09 2017-05-17 Lexicon Pharmaceuticals Inc Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
JP2015513557A (ja) * 2012-03-09 2015-05-14 レクシコン ファーマシューティカルズ インコーポレイテッド 疼痛の治療に対するアダプター関連キナーゼ1の阻害

Similar Documents

Publication Publication Date Title
JP2017507980A5 (US07794700-20100914-C00152.png)
JP2017520613A5 (US07794700-20100914-C00152.png)
JP2017535550A5 (US07794700-20100914-C00152.png)
JP2017527578A5 (US07794700-20100914-C00152.png)
JP2017504635A5 (US07794700-20100914-C00152.png)
JP2019528276A5 (US07794700-20100914-C00152.png)
FI3699181T3 (fi) Kiteinen muoto (s)-n-(5-((r)-2-(2,5-diluorifenyyli)-pyrrolidin-1-yyli)-pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidivetyysulfaatista
JP2015514060A5 (US07794700-20100914-C00152.png)
JP2016128501A5 (US07794700-20100914-C00152.png)
JP2017526711A5 (US07794700-20100914-C00152.png)
JP2020510661A5 (US07794700-20100914-C00152.png)
JP2019529514A5 (US07794700-20100914-C00152.png)
PH12015501517A1 (en) Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
MY196243A (en) Dihydropyrimidine Compounds and Their Application In Pharmaceuticals
JP2016522835A5 (US07794700-20100914-C00152.png)
BR112014001768A2 (pt) derivados de 2-(2,4,5-substituído-anilino)pirimidina como moduladores de egfr úteis para tratar câncer
JP2018530608A5 (US07794700-20100914-C00152.png)
EP4241772A3 (en) Process for the preparation of compounds useful for treating spinal muscular atrophy
JP2020502092A5 (US07794700-20100914-C00152.png)
JP2016529315A5 (US07794700-20100914-C00152.png)
JP2017514910A5 (US07794700-20100914-C00152.png)
JP2014525470A5 (US07794700-20100914-C00152.png)
JP2016503010A5 (US07794700-20100914-C00152.png)
JP2016529319A5 (US07794700-20100914-C00152.png)
JP2018507886A5 (US07794700-20100914-C00152.png)